Trial Profile

A Phase 1b Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide or in Combination With Pomalidomide for Multiple Myeloma

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 07 Aug 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ramantamig (Primary) ; Daratumumab; Pomalidomide
Indications Multiple myeloma
Focus Adverse reactions
Sponsors Janssen Research & Development

Most Recent Events

31 Jul 2026 Planned End Date changed from 2 Jan 2029 to 29 Jan 2029.
06 Jul 2026 Planned number of patients changed from 140 to 240.
06 Jul 2026 Planned primary completion date changed from 19 Nov 2027 to 2 Jan 2029.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com